Tarceva Survival Benefit Differentiates Oncologic From Iressa – Genentech
Executive Summary
The survival benefit seen in Genentech/OSI's Tarceva non-small cell lung cancer monotherapy trial shows it is a "better product" than AstraZeneca's Iressa, Genentech maintained April 26
You may also be interested in...
Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo
Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7
Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said
Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo
Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7